Bibliografia

  1. RCM DORMIDINA®.
  2. Ringdahl EN, Pereira SL, Delzell JE, Jr. Treatment of primary insomnia. J Am Board Fam Pract. 2004;17(3):212-9.
  3. Gillin JC, Byerley WF. Drug therapy: The diagnosis and management of insomnia. N Engl J Med. 1990;322(4):239-48.
  4. Brunton LL, Parker JK. Drugs acting on the central nervous system. In: Hardman. JG, Limbird LE, editors. Goodman & Gilman´s The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies, Inc. , 2006. p. 422-425.
  5. Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008;13(12):1027-38.
  6. Zimmerman DR. Sleep Aids. In: Zimmerman’s complete guide to non-prescription drugs. 2nd ed. Detroit (MI): Gale Research Inc.; 1992. p. 870-5.
  7. Brunton LL, Parker JK. Doxylamine Monograph. In: Hardman JG, Limbird LE, editors. Goodman & Gilman´s The pharmacological basis of therapeutics. Digital Edition. 11th ed [online]. New York: McGraw Hill; 2006. Disponível em: http://www.accessmedicine.com/resourceTOC.aspx?resourceID=28. Acedido em: janeiro, 2010.
  8. WHO. IARC. Monographs on the evaluation of carcinogenic risks to human. 2001;79:145-159. Disponível em: http://monographs.iarc.fr/ENG/Monographs/vol79/mono79-10.pdf. Acedido em: janeiro, 2014.
  9. Montoro J, Sastre J, Bartra J, del Cuvillo A, Davila I, Jauregui I, et al. Effect of H1 antihistamines upon the central nervous system. J Investig Allergol Clin Immunol. 2006; 16(Suppl. 1): 24-8.
  10. Skidgel RA, Kaplan AP, Erdöos EG. Histamine, Bradykinin, and their Antagonists. In: Bruton L, Chabner B, Knollman B, editors. Goodman & Gilman’s The Pharmacological Basis Of Therapeutics. 12th Edition. New York: The McGraw-Hill 2011. p. 911-926.
  11. Videla S, Lahjou M, Guibord P, Xu Z, Tolrà C, Encina G, Sicard E, Sans A. Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers. Drugs R D. 2012;12(4):217-25.
  12. Friedman H, Greenblatt DJ. The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection. J Clin Pharmacol. 1985;25(6):448-51.
  13. Friedman H, Greenblatt DJ, Scavone JM, Burstein ES, Ochs HR, Harmatz JS, et al. Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women. Clin Pharmacokinet. 1989;16(5):312-6.
  14. Thompson GA, St Peter JV, Heise MA, Horowitz ZD, Salyers GC, Charles TT, et al. Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. J Pharm Sci. 1996;85(11):1242-7.
  15. Slikker W, Jr., Holder CL, Lipe GW, Bailey JR, Young JF. Pharmacokinetics of doxylamine, a component of Bendectin, in the rhesus monkey. Reprod Toxicol. 1989;3(3):187-96.
  16. Videla S, Cebrecos J, Lahjou M, Wagner F, Guibord P, Xu Z, Cabot A, Encabo M, Encina G, Sicard E, Sans A. Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: a single-dose, randomized, two-period crossover study in healthy volunteers. Drugs R D. 2013;13(2):129-35.
  17. Presa IJ. H1 Antihistamines: a review. Alergol Inmunol Clin. 1999;14(5):300-12.
  18. Hausser-Hauw C, Scheck F, Pello JY, Lebeau B. Effect on sleep architecture and residual effect of a dose of 15 mg of doxylamine in healthy volunteers. Sem Hop. 1995;71(23-24):742-50.
  19. Bishai R, Mazzotta P, Atanackovic G, Levichek Z, Pole M, Magee LA, et al. Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of diclectin (doxylamine-B6). Can J Clin Pharmacol. 2000;7(3):138-43.
  20. Doxylamine Succinate. In: Sweetman SC, editor. Martindale – The Complete Drug Reference. 35th Edition. Taunton (MA): Pharmaceutical Press, 2007. p. 522-523.
  21. Martinez-Gomez MA, Carril-Aviles MM, Sagrado S, Villanueva-Camanas RM, Medina-Hernandez MJ. Characterization of antihistamine-human serum protein interactions by capillary electrophoresis. J Chromatogr A. 2007;1147(2):261-9.
  22. Holder CL, Thompson HC, Jr., Gosnell AB, Siitonen PH, Korfmacher WA, Cerniglia CE, et al. Metabolism of doxylamine succinate in Fischer 344 rats. Part II: Nonconjugated urinary and fecal metabolites. J Anal Toxicol. 1987;11(3):113-21.
  23. Gielsdorf W, Schubert K. Biotransformation of doxylamine: isolation, identification and synthesis of some metabolites (author’s transl). J Clin Chem Clin Biochem. 1981; 19(7): 485-90.
  24. Ganes DA, Midha KK. Identification in in vivo acetylation pathway for N-dealkylated metabolites of doxylamine in humans. Xenobiotica. 1987;17(8):993-9.
  25. Luo H, Hawes EM, McKay G, Korchinski ED, Midha KK. N(+)-glucuronidation of aliphatic tertiary amines, a general phenomenon in the metabolism of H1-antihistamines in humans. Xenobiotica. 1991;21(10):1281-8.
  26. Luna BG, Scavone JM, Greenblatt DJ. Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. J Clin Pharmacol. 1989;29(3):257-60.
  27. Sjöqvist F, Lasagna L. The hypnotic efficacy of doxylamine. Clin Pharmacol Ther. 1967;8(1):48-54.
  28. Rickels K. Doxylamine succinate in insomniac family-practice patients – A double-blind study. Current Therapeutic Research. 1984;35(4):532-40.
  29. Lenau HP, P.; Höxter, G. and Maier-Lenz, H. Action and tolerance of the pills to drink “Gitallum” in patients with sleep disorders. Terapiewoche. 1984;34:239-42.
  30. Smith GM, Smith PH. Effects of doxylamine and acetaminophen on postoperative sleep. Clin Pharmacol Ther. 1985;37(5):549-57.
  31. Lemoine P SF, Pello JY. Absence of withdrawal signs following discontinuation of treatment with doxylamine. A placebo-controlled study. Sem Hop. 1995;71(23-24):751-60.
  32. Schadeck BCM, Amsellem D, Cohen A, Peraudeau P and Scheck F. Efficacité comparative de la doxylamine (15 mg) et du zolpidem (10 mg) dans le traitement de l’insomnie commune : Une étude contrôlée versus placebo = Comparative efficacy of doxylamine (15 mg) and zolpidem (10 mg) for the treatment of common insomnia : A placebo-controlled study. Sem Hop. 1996;72(13-14):428-39.
  33. Lee YD, Lee ST. Acute pancreatitis and acute renal failure complicating doxylamine succinate intoxication. Vet Hum Toxicol. 2002;44(3):165-6.
  34. Bockholdt B, Klug E, Schneider V. Suicide through doxylamine poisoning. Forensic Sci Int. 2001;119(1):138-40.
  35. Koppel C, Tenczer J, Ibe K. Poisoning with over-the-counter doxylamine preparations: an evaluation of 109 cases. Hum Toxicol. 1987;6(5):355-9.
  36. Mendoza FS, Atiba JO, Krensky AM, Scannell LM. Rhabdomyolysis complicating doxylamine overdose. Clin Pediatr (Phila). 1987;26(11):595-7.
  37. Leybishkis B, Fasseas P, Ryan KF. Doxylamine overdose as a potential cause of rhabdomyolysis. Am J Med Sci. 2001;322(1):48-9.
  38. Jo YI, Song JO, Park JH, Koh SY, Lee SM, Seo TH, et al. Risk factors for rhabdomyolysis following doxylamine overdose. Hum Exp Toxicol. 2007;26(8):617-21.
  39. Kim HJ, Oh SH, Youn CS, Wee JH, Kim JH, Jeong WJ, Kim SH, Jeong SH, Park KN. The associative factors of delayed-onset rhabdomyolysis in patients with doxylamine overdose. Am J Emerg Med. 2011;29(8):903-7.
  40. Syed H, Som S, Khan N, Faltas W. Doxylamine toxicity: seizure, rhabdomyolysis and false positive urine drug screen for methadone. BMJ Case Rep. 2009;2009. pii: bcr09.2008.0879.
  41. Bliwise DL. Treating insomnia: pharmacological and nonpharmacological approaches. J Psychoactive Drugs. 1991;23(4):335-41.
  42. Tashiro M, Duan X, Kato M, Miyake M, Watanuki S, Ishikawa Y, Funaki Y, Iwata R, Itoh M, Yanai K. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br J Clin Pharmacol. 2008;65(6):811-21.
  43. Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther. 2007;113(1):1-15.
  44. Hishinuma S, Sato Y, Kobayashi Y, Komazaki H, Saito M. Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008;107(1):66-79.
  45. Montoro J, Sastre J, Bartra J, Del Cuvillo A, Dávila I, Jáuregui I, Mullol J, Valero AL. Effect of H1 antihistamines upon the central nervous system. J Investig Allergol Clin Immunol. 2006;16(Suppl.1):24-28.
  46. McCormick DA, Williamson A. Modulation of neuronal firing mode in cat and guinea pig LGNd by histamine: possible cellular mechanisms of histaminergic control of arousal. J Neurosci. 1991;11(10):3188-99.
  47. Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, et al. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology. 2004;72(2):92-8.
  48. McBride WG. Doxylamine succinate induced dysmorphogenesis in the marmoset (Callithrix Jaccus). IRCS Med Sci. 1985;13(3):225-6.
  49. Hey JA, Del Prado M, Cuss FM, Egan RW, Sherwood J, Lin CC, et al. Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs. Clin Exp Allergy. 1995;25(10):974-84.
  50. Marzanatti M, Monopoli A, Trampus M, Ongini E. Effects of nonsedating histamine H1-antagonists on EEG activity and behavior in the cat. Pharmacol Biochem Behav. 1989;32(4):861-6.
  51. Wauquier A, Van den Broeck WA, Awouters F, Janssen PA. A comparison between astemizole and other antihistamines on sleep-wakefulness cycles in dogs. Neuropharmacology. 1981;20(9):853-9.
  52. Criado PR, Criado RF, Maruta CW, Machado Filho C. Histamine, histamine receptors and antihistamines: new concepts. An Bras Dermatol. 2010;85(2):195-210.
  53. Brown BB, Werner HW. The pharmacologic properties of 2-[alpha-(2- dimethylaminoethoxy)-alpha-methylbenzyl]-pyridine succinate, a new antihistaminic agent. J Lab Clin Med. 1948;33(3):325-31.
  54. Takeda N, Morita M, Horii A, Nishiike S, Kitahara T, Uno A. Neural mechanisms of motion sickness. J Med Invest. 2001;48(1-2):44-59.
  55. Schuller DE, Turkewitz D. Adverse effects of antihistamines. Postgrad Med. 1986;79(2):75-86.
  56. TOXNET. Doxylamine succinate. Disponível em: http://toxnet.nlm.nih.gov/cgi-bin/sis/search. Acedido em: janeiro, 2014.
  57. Thompson CR, Werner HW. Chronic toxicity studies on decapryn cussinate (2-[alpha-(2-dimethylaminoethoxy)-alpha-methylbenzyl]-pyridine succinate. J Am Pharm Assoc Am Pharm Assoc. 1948;37(8):311-4.
  58. Slikker W, Jr., Holder CL, Lipe GW, Bailey JR, Young JF. Pharmacokinetics of doxylamine, a component of Bendectin, in the rhesus monkey. Reprod Toxicol. 1989;3(3):187-96.
  59. Slikker W, Jr., Holder CL, Lipe GW, Korfmacher WA, Thompson HC, Jr., Bailey JR. Metabolism of 14C-labeled doxylamine succinate (Bendectin) in the rhesus monkey (Macaca mulatta). J Anal Toxicol. 1986;10(3):87-92.
  60. Pelser A, Muller DG, du Plessis J, du Preez JL, Goosen C. Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats. Biopharm Drug Dispos. 2002;23(6):239-44.
  61. Rowland JM, Slikker W, Jr., Holder CL, Denton R, Prahalada S, Young JF, et al. Pharmacokinetics of doxylamine given as Bendectin in the pregnant monkey and baboon. Reprod Toxicol. 1989;3(3):197-202.
  62. Roberts LG, Luck W, Holder CL, Scott WJ, Nau H, Slikker W, Jr. Embryo-maternal distribution of basic compounds in the CD-1 mouse: doxylamine and nicotine. Toxicol Appl Pharmacol. 1989;97(1):134-40.
  63. WHO. IARC. Monographs on the evaluation of carcinogenic risks to human. 2001;79:145-159. Disponível em: http://monographs.iarc.fr/ENG/Monographs/vol79/mono79-10.pdf.Acedido em: janeiro, 2014.
  64. Bookstaff RC, Murphy VA, Skare JA, Minnema D, Sanzgiri U, Parkinson A. Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice. Toxicol Appl Pharmacol. 1996;141(2):584-94.
  65. Holder CL, Thompson HC, Jr., Gosnell AB, Siitonen PH, Korfmacher WA, Cerniglia CE, et al. Metabolism of doxylamine succinate in Fischer 344 rats. Part II: Nonconjugated urinary and fecal metabolites. J Anal Toxicol. 1987;11(3):113-21.
  66. Ganes DA, Hindmarsh KW, Midha KK. Doxylamine metabolism in rat and monkey. Xenobiotica. 1986;16(9):781-94.
  67. Holder CL, Siitonen PH, Slikker W, Jr., Branscomb CJ, Korfmacher WA, Thompson HC, Jr., et al. Metabolism of doxylamine succinate in Fischer 344 rats. Part III: Conjugated urinary and fecal metabolites. J Anal Toxicol. 1990;14(4):247-51.
  68. Thompson HC, Jr., Gosnell AB, Holder CL, Siitonen PH, Rowland KL, Cmarik JL. Metabolism of doxylamine succinate in Fischer 344 rats. Part I: Distribution and excretion. J Anal Toxicol. 1986;10(1):18-23.
  69. Snyder FH, Klahm GR, Werner HW. Studies on the metabolism of 2-[ alpha-(2-dimethylaminoethoxy)-alpha-methylbenzyl]-pyridine succinate (decapryn succinate). J Am Pharm Assoc Am Pharm Assoc. 1948;37(10):420-3.
  70. ChemIDplus. Doxylamine succinate. Disponível em: http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFull.jsp?calledFrom=lite. Acedido em: janeiro, 2014.
  71. Jackson CD, Blackwell BN. Subchronic studies of doxylamine in B6C3F1 mice. Fundam Appl Toxicol. 1988;10(2):254-61.
  72. Jackson CD, Blackwell BN. Subchronic studies of doxylamine in Fischer 344 rats. Fundam Appl Toxicol. 1988;10(2):243-53.
  73. Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K, Speck W. Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. Environ Mutagen. 1987;9(Suppl. 9):1-109.
  74. Althaus FR, Lawrence SD, Sattler GL, Pitot HC. DNA damage induced by the antihistaminic drug methapyrilene hydrochloride. Mutat Res. 1982;103(3-6):213-8.
  75. Budroe JD, Shaddock JG, Casciano DA. A study of the potential genotoxicity of methapyrilene and related antihistamines using the hepatocyte/DNA repair assay. Mutat Res. 1984;135(2):131-7.
  76. Toraason M, Bohrman JS, Krieg E, Combes RD, Willington SE, Zajac W, et al. Evaluation of the V79 cell metabolic co-operation assay as a screen in vitro for developmental toxicants. Toxic in Vitro. 1991;6(2):165-74.
  77. Muller L, Korte A, Madle S. Mutagenicity testing of doxylamine succinate, an antinauseant drug. Toxicol Lett. 1989;49(1):79-86.
  78. Jackson CD, Sheldon W. Two-year toxicity study of doxylamine succinate in B6C3F1 mice. J Am Col Toxic. 1993;12:311-21.
  79. Brandes LJ, Warrington RC, Arron RJ, Bogdanovic RP, Fang W, Queen GM, et al. Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates. J Natl Cancer Inst. 1994;86(10):770-5.
  80. Jackson CD, Blackwell BN. 2-year toxicity study of doxylamine succinate in the Fischer 344 rat. J Am Col Toxic. 1993;12:1-11.
  81. FDA. Department of Health and Human Services. Determination that Bendectin was not withdrawn from sale for reasons of safety or effectiveness. Federal Register. 1999;64(152):43190-1. Disponível em: http://www.gpo.gov/fdsys/pkg/FR-1999-08-09/pdf/99-20362.pdf. Acedido em: janeiro, 2014.
  82. Smith MK, Kimmel GL, Kochhar DM, Shepard TH, Spielberg SP, Wilson JG. A selection of candidate compounds for in vitro teratogenesis test validation. Teratog Carcinog Mutagen. 1983;3(6):461-80.
  83. American Society of Health-System Pharmacists. McEvoy GK, & Snow EK (Eds). American Hospital Formulary Service (AHFS) DRUG INFORMATION 2013. Antihistamine Drugs. Doxylamine Succinate. Bethesda (MD): American Society of Health-System Pharmacists, 2013. Disponível em: http://www.ahfsdruginformation.com/support/not_in_print/a382537.aspx. Acedido em: janeiro, 2014.
  84. Renault JY, Caillaud JM, Chevalier J. Ultrastructural characterization of normal and abnormal chondrogenesis in micromass rat embryo limb bud cell cultures. Toxicol Appl Pharmacol. 1995;130(2):177-87.
  85. Friedman H, Greenblatt DJ. The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection. J Clin Pharmacol. 1985;25(6):448-51.
  86. Gibson JP, Staples RE, Larson EJ, Kuhn WL, Holtkamp DE, Newberne JW. Teratology and reproduction studies with an antinauseant. Toxicol Appl Pharmacol. 1968;13(3):439-47.
  87. Sturman G, Freeman P, Meade HM, Seeley NA. Rat fetal and postnatal development after treatment in utero with histamine H1 antagonists. Inflamm Res. 1995;44(Suppl.1):S74-75.
  88. McBride WG. Teratogenic effect of doxylamine succinate in New Zealand white rabbits. IRCS Med Sci. 1984;12:536-37.
  89. McBride WG, Hicks LJ. Acetylcholine and choline levels in rabbit fetuses exposed to anticholinergics. Int J Dev Neurosci. 1987;5(2):117-25.
  90. Tyl RW, Price CJ, Marr MC, Kimmel CA. Developmental toxicity evaluation of Bendectin in CD rats. Teratology. 1988;37(6):539-52.
  91. Hendrickx AG, Cukierski M, Prahalada S, Janos G, Rowland J. Evaluation of bendectin embryotoxicity in nonhuman primates: I. Ventricular septal defects in prenatal macaques and baboon. Teratology. 1985;32(2):179-89.
  92. Hendrickx AG, Cukierski M, Prahalada S, Janos G, Booher S, Nyland T. Evaluation of bendectin embryotoxicity in nonhuman primates: II. Double-blind study in term cynomolgus monkeys. Teratology. 1985;32(2):191-4.
  93. Morin CM, Espie CA. Assessment and Differential Diagnosis of Insomnia. Insommnia. A Clinical Guide to Assessment and Treatment. 1st Edition. New York: Kluwer Academic/Plenum Publishers, 2003. p.33.
  94. Paiva T, Penzel T. Centro de Medicina do Sono – Manual Prático. 1st Edition.Lisboa: Lidel – edições técnicas, lda, 2011. p.5-89.
  95. American Psychiatric Association. Sleep-Wake Disorders. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington (VA): American Psychiatric Association, 2013. p.361-368.